Kempner Capital Management Inc. Takes $2.16 Million Position in Kenvue Inc. $KVUE

Kempner Capital Management Inc. purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 133,214 shares of the company’s stock, valued at approximately $2,162,000. Kenvue makes up 1.8% of Kempner Capital Management Inc.’s holdings, making the stock its 26th biggest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the company. AlphaQuest LLC bought a new stake in Kenvue in the first quarter worth approximately $77,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Kenvue by 8.7% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 78,019 shares of the company’s stock valued at $1,871,000 after purchasing an additional 6,214 shares during the last quarter. Truvestments Capital LLC bought a new stake in Kenvue in the first quarter worth $37,000. Lansforsakringar Fondforvaltning AB publ boosted its holdings in Kenvue by 0.4% in the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 616,092 shares of the company’s stock worth $14,774,000 after purchasing an additional 2,453 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in Kenvue during the first quarter worth $2,584,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $17.20 on Friday. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a market cap of $32.95 billion, a P/E ratio of 22.93 and a beta of 0.60. The business’s 50 day moving average is $16.44 and its two-hundred day moving average is $18.73. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. Kenvue’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the company posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is currently 110.67%.

Insider Activity at Kenvue

In related news, Director Jeffrey C. Smith bought 3,200,000 shares of Kenvue stock in a transaction that occurred on Friday, December 12th. The stock was acquired at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the purchase, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.68% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the subject of several recent analyst reports. Canaccord Genuity Group reiterated a “hold” rating and set a $15.00 price target (down previously from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. JPMorgan Chase & Co. decreased their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Zacks Research raised shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Finally, The Goldman Sachs Group decreased their price objective on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.23.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.